Boryung eying sales of 10 billion won with new drug

Published: 2011-09-19 06:58:00

Updated: 2011-09-19 06:58:00

Boryung Pharmaceutical Co. says its new drug for hypertension “Kanarb (fimasartan)”, angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, is expected to achieve a 10 billion won in sales within one year since its launch in March.

Such robust sales will be possible ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK